VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On April 5, 2017, VBI Vaccines Inc. (the Company) issued a press
release announcing that David E. Anderson, Ph.D., the Companys
Chief Scientific Officer, and Francisco Diaz-Mitoma, M.D., Ph.D,
the Companys Chief Medical Officer, will present updates on the
Companys eVLP Platform and Sci-B-Vac vaccine, respectively, at
the World Vaccine Congress in Washington, D.C. on Tuesday, April
11, 2017. A copy of the press release is furnished herewith as
Exhibit 99.1 and incorporated by reference in this Item 7.01.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, and shall not
be deemed filed with the U.S. Securities and Exchange Commission
(the SEC) nor incorporated by reference into any filing made
under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | Press Release dated April 5, 2017. |
* Furnished herewith
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda). VBI VACCINES INC. (TSE:VBV) Recent Trading Information
VBI VACCINES INC. (TSE:VBV) closed its last trading session 00.00 at 7.52 with 3,784 shares trading hands.
